Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL28197187 | 0.97 | KIF11 (0.46) | KIF11KCNN4TSHRALDH1A1MAPK1 | |
| SCHEMBL2876796 | 0.84 | KIF11 (0.58) | KIF11KCNN4TSHRALDH1A1CYP1A2 | |
| SCHEMBL9408957 | 0.84 | KIF11 (0.58) | KIF11TSHR | |
| SCHEMBL12308063 | 0.83 | ESR1 (0.44) | KIF11KCNN4TSHRALDH1A1MAPK1 | |
| SCHEMBL7105336 | 0.81 | KIF11 (0.46) | KIF11KCNN4TSHR | |
| SCHEMBL7715769 | 0.80 | KIF11 (0.48) | KIF11KCNN4TSHRALDH1A1MAPK1 | |
| SCHEMBL9408986 | 0.79 | KIF11 (0.54) | KIF11 | |
| SCHEMBL2879044 | 0.79 | KIF11 (0.62) | KIF11 | |
| SCHEMBL977257 | 0.79 | KIF11 (0.62) | KIF11 | |
| SCHEMBL9408990 | 0.79 | KIF11 (0.64) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210189392-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | claimed |
| CN-104725628-B | A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group | 厦门赛诺邦格生物科技股份有限公司 | 2018-04-17 | — | — | CN | claimed |
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | claimed |
| CN-104530415-B | A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-01 | — | — | CN | claimed |
| CN-104109235-B | A kind of single functionalized poly (ethylene glycol), preparation method and its bio-related substance with nitrogen-atoms branch centers | 厦门赛诺邦格生物科技股份有限公司 | 2017-07-18 | — | — | CN | claimed |
| CN-104725628-A | Single functional branched polyethylene glycol containing degradable radical, preparation method and biorelevant substance of single functional branched polyethylene glycol | XIAMEN SINOPEG BIOTECH CO LTD | 2015-06-24 | — | — | CN | claimed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104109235-A | Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter | XIAMEN SINOPEG BIOTECH CO LTD | 2014-10-22 | — | — | CN | claimed |
| WO-2008013427-A1 | ORGANIC TFTS AND METHOD FOR FABRICATING THE SAME | LG CHEM, LTD. (KR) | 2008-01-31 | — | — | WO | claimed |
| WO-2004061416-A2 | METHODS FOR ATTACHING MOLECULES | GENORX, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040048241-A1 | Methods for attaching molecules | GENORX, INC. | 2004-03-11 | — | — | US | claimed |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | CHIRON CORPORATION | 2002-11-14 | — | — | US | claimed |
| WO-2002081637-A2 | PEPTIDES INCORPORATING CHEMOSELECTIVE FUNCTIONALITIES | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
| US-5635371-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-06-03 | — | — | US | claimed |
| JP-1117856-A | — | — | None | — | — | JP | disclosed |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| EP-0238285-A2 | 2-Heterocyclylthio penems | SCHERING CORPORATION (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0222889-A1 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1987-05-27 | — | — | EP | disclosed |
| WO-1986006726-A1 | CYTIDINE ANALOGS | INTEGRATED GENETICS, INC. (US) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, NSUN2, STAT1 | KIF11 4625/4885KCNN4 3119/4885TSHR 924/4885 |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | VIP, PCNA, DNPEP | KIF11 3599/4885KCNN4 4438/4885TSHR 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.